The FDA ending the semaglutide shortage could significantly impede Hims GLP-1 business as the Food Drug and Cosmetic Act prohibits compounding of products that are essentially a copy of another drug on the market, unless the copied drug is labeled as currently in shortage on the FDAs drug shortage list
Am J Kidney Dis 48:706711
However, subgroup analyses from FLOW raised important questions regarding combination therapy
Even in the hypertension literature, it was ignored as a first line option in ALLHAT (Furberg et al, JAMA 2002) despite being approved in 1960 by the FDA at the same time as chlorthalidone
En este mismo marco conceptual, deberan plantearse experimentos que comparen la eficacia cardioprotectora de diferentes terapias basadas en GLP-1, sobre todo teniendo en cuenta que los agonistas del GLP-1R y los inhibidores de la DPP-4 presentan diferentes acciones dependiendo de si se evalan en el contexto metablico o en el cardiovascular14,72,73
However, Jardiance may be used at lower eGFR levels (20 mL/min/1.73m) for heart failure or chronic kidney disease indications per the SmPC
